The dopamine hypothesis of bipolar affective disorder: The state of the art and implications for treatment

Molecular Psychiatry

Volumn 22, Issue 5, 2017, Pages 666-679

  Ashok, A H ^a,b,c,d   Marques, T R ^a,b,c,d   Jauhar, S ^a,b,c,d   Nour, M M ^a,b,c   Goodwin, G M ^e   Young, A H ^c,d   Howes, O D ^a,b,c,d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^e WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; MOOD STABILIZER;

AUTOPSY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; EVIDENCE BASED MEDICINE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GENE EXPRESSION; HUMAN; IN VIVO STUDY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; REWARD; SYSTEMATIC REVIEW; ANIMAL; METABOLISM; SYNAPTIC TRANSMISSION;

ANIMALS; BIPOLAR DISORDER; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION;

EID: 85015073112     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2017.16     Document Type: Review

References (150)

1. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005;62:1322-1330.
2. Judd LL, Schettler PJ, Solomon DA, Maser JD, Coryell W, Endicott J et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord 2008;108:49-58.
3. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-2196.
4. Merikangas KR, Cui L, Kattan G, Carlson GA, Youngstrom EA, Angst J. Mania with and without depression in a community sample of US adolescents. Arch Gen Psychiatry 2012;69:943-951.
5. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68:241-251.
6. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2015;387:1561-1572.
7. Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord 2011;129:79-83.
8. Jann MW. Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. Am Health Drug Benefits 2014;7:489-499.
9. Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry 2015;20:661-670.
10. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161:217-222.
11. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006;11:227-240.
12. Ketter TA, Miller S, Dell'Osso B, Wang PW. Treatment of bipolar disorder: review of evidence regarding quetiapine and lithium. J Affect Disord 2016;191:256-273.
13. Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2014;2:15.
14. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multipletreatments meta-analysis. Lancet 2011;378:1306-1315.
15. Young AH, McElroy SL, Olausson B, Paulsson B. A randomised, placebocontrolled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry 2014;15:96-112.
16. Giles JJ, Bannigan JG. Teratogenic and developmental effects of lithium. Curr Pharm Des 2006;12:1531-1541.
17. Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Expert Opin Drug Saf 2012;11:425-437.
18. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379:721-728.
19. Tissot R. The common pathophysiology of monaminergic psychoses: a new hypothesis. Neuropsychobiology 1975;1:243-260.
20. Wittenborn JR. Deductive approaches to the catecholamine hypothesis of affective disorders. J Nerv Ment Dis 1974;158:320-324.
21. Singh MM. A unifying hypothesis on the biochemical basis of affective disorder. Psychiatr Q 1970;44:706-724.
22. Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007; (434): 41-49.
23. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord 2009;11:787-806.
24. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009;15:2550-2559.
25. Harrison PJ, Cipriani A, Harmer CJ, Nobre AC, Saunders K, Goodwin GM et al. Innovative approaches to bipolar disorder and its treatment. Ann N Y Acad Sci 2016;1366:76-89.
26. Berggren U, Tallstedt L, Ahlenius S, Engel J. The effect of lithium on amphetamineinduced locomotor stimulation. Psychopharmacology 1978;59:41-45.
27. Gould TJ, Keith RA, Bhat RV. Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav Brain Res 2001;118:95-105.
28. Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ et al. A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 2009;66:1072-1080.
29. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA. The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav 2010;96:7-15.
30. Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH. Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm 2002;109:433-440.
31. Sidor MM, Spencer SM, Dzirasa K, Parekh PK, Tye KM, Warden MR et al. Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol Psychiatry 2015;20:1406-1419.
32. Winter C, von Rumohr A, Mundt A, Petrus D, Klein J, Lee T et al. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 2007;184:133-141.
33. Tye KM, Mirzabekov JJ, Warden MR, Ferenczi EA, Tsai HC, Finkelstein J et al. Dopamine neurons modulate neural encoding and expression of depressionrelated behaviour. Nature 2013;493:537-541.
34. Kaalund SS, Newburn EN, Ye T, Tao R, Li C, Deep-Soboslay A et al. Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain. Mol Psychiatry 2014;19:1258-1266.
35. Zhan L, Kerr JR, Lafuente MJ, Maclean A, Chibalina MV, Liu B et al. Altered expression and coregulation of dopamine signalling genes in schizophrenia and bipolar disorder. Neuropathol Appl Neurobiol 2011;37:206-219.
36. Glantz LA, Gilmore JH, Overstreet DH, Salimi K, Lieberman JA, Jarskog LF. Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophr Res 2010;118:292-299.
37. Pantazopoulos H, Stone D, Walsh J, Benes FM. Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics. Synapse 2004;54:147-155.
38. Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry 2004;9:544.
39. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 2009;34:662-671.
40. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012;69:776-786.
41. Pearlson GD, Wong DF, Tune LE, Ross CA, Chase GA, Links JM et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 1995;52:471-477.
42. Wong DF, Pearlson GD, Tune LE, Young LT, Meltzer CC, Dannals RF et al. Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997;17:331-342.
43. Swart JA, van der Werf JF, Wiegman T, Paans AM, Vaalburg W, Korf J. In vivo binding of spiperone and N-methylspiperone to dopaminergic and serotonergic sites in the rat brain: multiple modeling and implications for PET scanning. J Cereb Blood Flow Metab 1990;10:297-306.
44. Yatham LN, Liddle PF, Lam RW, Shiah IS, Lane C, Stoessl AJ et al. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and moodstabilizer- naive patients with nonpsychotic mania. Am J Psychiatry 2002;159:1718-1723.
45. Yatham LN, Liddle PF, Shiah IS, Lam RW, Ngan E, Scarrow G et al. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry 2002;159:768-774.
46. Anand A, Barkay G, Dzemidzic M, Albrecht D, Karne H, Zheng QH et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord 2011;13:406-413.
47. Chang TT, Yeh TL, Chiu NT, Chen PS, Huang HY, Yang YK et al. Higher striatal dopamine transporters in euthymic patients with bipolar disorder: a SPECT study with [Tc] TRODAT-1. Bipolar Disord 2010;12:102-106.
48. Zubieta JK, Huguelet P, Ohl LE, Koeppe RA, Kilbourn MR, Carr JM et al. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am J Psychiatry 2000;157:1619-1628.
49. Suhara T, Nakayama K, Inoue O, Fukuda H, Shimizu M, Mori A et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 1992;106:14-18.
50. Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000;157:1108-1114.
51. Berridge KC. From prediction error to incentive salience: Mesolimbic computation of reward motivation. Eur J Neurosci 2012;35:1124-1143.
52. Schultz W. Dopamine signals for reward value and risk: basic and recent data. Behav Brain Funct 2010;6:1-9.
53. Winton-Brown TT, Fusar-Poli P, Ungless MA, Howes OD. Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci 2014;37:85-94.
54. Howes OD, Nour MM. Dopamine and the aberrant salience hypothesis of schizophrenia. World Psychiatry 2016;15:3-4.
55. Tsai HC, Zhang F, Adamantidis A, Stuber GD, Bonci A, de Lecea L et al. Phasic firing in dopaminergic neurons is sufficient for behavioral conditioning. Science2009;324:1080-1084.
56. Schultz W. Updating dopamine reward signals. Curr Opin Neurobiol 2013;23:229-238.
57. Schott BH, Minuzzi L, Krebs RM, Elmenhorst D, Lang M, Winz OH et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neurosci 2008;28:14311-14319.
58. Bartra O, McGuire JT, Kable JW. The valuation system: a coordinate-based metaanalysis of BOLD fMRI experiments examining neural correlates of subjective value. NeuroImage 2013;76:412-427.
59. Diekhof EK, Kaps L, Falkai P, Gruber O. The role of the human ventral striatum and the medial orbitofrontal cortex in the representation of reward magnitude - an activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing. Neuropsychologia 2012;50:1252-1266.
60. Liu X, Hairston J, Schrier M, Fan J. Common and distinct networks underlying reward valence and processing stages: a meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev 2011;35:1219-1236.
61. Nusslock R, Young CB, Damme KSF. Elevated reward-related neural activation as a unique biological marker of bipolar disorder: assessment and treatment implications. Behav Res Therapy 2014;62:74-87.
62. Aarts E, Roelofs A, Franke B, Rijpkema M, Fernandez G, Helmich RC et al. Striatal dopamine mediates the interface between motivational and cognitive control in humans: evidence from genetic imaging. Neuropsychopharmacology 2010;35:1943-1951.
63. Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF. Variation in dopamine genes influences responsivity of the human reward system. Proc Natl Acad Sci USA 2009;106:617-622.
64. Forbes EE, Brown SM, Kimak M, Ferrell RE, Manuck SB, Hariri AR. Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Mol Psychiatry 2009;14:60-70.
65. Jonasson LS, Axelsson J, Riklund K, Braver TS, Ogren M, Backman L et al. Dopamine release in nucleus accumbens during rewarded task switching measured by [(1)(1)C]raclopride. NeuroImage 2014;99:357-364.
66. Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007;30:259-288.
67. van der Schaaf ME, van Schouwenburg MR, Geurts DE, Schellekens AF, Buitelaar JK, Verkes RJ et al. Establishing the dopamine dependency of human striatal signals during reward and punishment reversal learning. Cereb Cortex 2014;24:633-642.
68. Knutson B, Gibbs SEB. Linking nucleus accumbens dopamine and blood oxygenation. Psychopharmacology 2007;191:813-822.
69. Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 2006;442:1042-1045.
70. Abler B, Greenhouse I, Ongur D, Walter H, Heckers S. Abnormal reward system activation in mania. Neuropsychopharmacology 2008;33:2217-2227.
71. Bermpohl F, Kahnt T, Dalanay U, Hägele C, Sajonz B, Wegner T et al. Altered representation of expected value in the orbitofrontal cortex in Mania. Hum Brain Mapp 2010;31:958-969.
72. Caseras X, Lawrence NS, Murphy K, Wise RG, Phillips ML. Ventral striatum activity in response to reward: differences between bipolar i and II disorders. Am J Psychiatry 2013;170:533-541.
73. Chase HW, Nusslock R, Almeida JR, Forbes EE, Labarbara EJ, Phillips ML. Dissociable patterns of abnormal frontal cortical activation during anticipation of an uncertain reward or loss in bipolar versus major depression. Bipolar Disord 2013;15:839-854.
74. Dutra S, Cunningham W, Kober H, Gruber J. Elevated striatal reactivity across monetary and social rewards in bipolar I disorder. J Abnorm Psychol 2015;124:890-904.
75. Linke J, King AV, Rietschel M, Strohmaier J, Hennerici M, Gass A et al. Increased medial orbitofrontal and amygdala activation: evidence for a systems-level endophenotype of bipolar I disorder. Am J Psychiatry 2012;169:316-325.
76. Mason L, O'Sullivan N, Montaldi D, Bentall RP, El-Deredy W. Decision-making and trait impulsivity in bipolar disorder are associated with reduced prefrontal regulation of striatal reward valuation. Brain 2014;137:2346-2355.
77. Nusslock R, Almeida J, Forbes E, Versace A, Frank E, LeBarbara E et al. Waiting to win: elevated striatal and orbitofrontal cortical activity during reward anticipation in euthymic bipolar disorder adults. Bipolar Disord 2012;14:249-260.
78. Redlich R, Dohm K, Grotegerd D, Opel N, Zwitserlood P, Heindel W et al. Reward processing in unipolar and bipolar depression: a functional MRI study. Neuropsychopharmacology 2015;40:1-28.
79. Satterthwaite TD, Kable JW, Vandekar L, Katchmar N, Bassett DS, Baldassano CF et al. Common and dissociable dysfunction of the reward system in bipolar and unipolar depression reward dysfunction in depression. Neuropsychopharmacology 2015;40:1-11.
80. Singh MK, Chang KD, Kelley RG, Cui X, Sherdell L, Howe ME et al. Reward processing in adolescents with bipolar I disorder. J Am Acad Child Adolesc Psychiatry 2013;52:68-83.
81. Trost S, Diekhof EK, Zvonik K, Lewandowski M, Usher J, Keil M et al. Disturbed anterior prefrontal control of the mesolimbic reward system and increased impulsivity in bipolar disorder. Neuropsychopharmacology 2014;39:1914-1923.
82. Yip SW, Worhunsky PD, Rogers RD, Goodwin GM. Hypoactivation of the ventral and dorsal striatum during reward and loss anticipation in antipsychotic and mood stabilizer-naive bipolar disorder. Neuropsychopharmacology 2015;40:658-666.
83. Dichter GS, Kozink RV, McClernon FJ, Smoski MJ. Remitted major depression is characterized by reward network hyperactivation during reward anticipation and hypoactivation during reward outcomes. J Affect Disord 2012;136:1126-1134.
84. Hagele C, Schlagenhauf F, Rapp M, Sterzer P, Beck A, Bermpohl F et al. Dimensional psychiatry: reward dysfunction and depressive mood across psychiatric disorders. Psychopharmacology 2015;232:331-341.
85. Radua J, Schmidt A, Borgwardt S, Heinz A, Schlagenhauf F, McGuire P et al. Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis. JAMA Psychiatry 2015;72:1243-1251.
86. Yan C, Yang T, Yu QJ, Jin Z, Cheung EF, Liu X et al. Rostral medial prefrontal dysfunctions and consummatory pleasure in schizophrenia: a meta-analysis of functional imaging studies. Psychiatry Res 2015;231:187-196.
87. Asghar SJ, Tanay VA, Baker GB, Greenshaw A, Silverstone PH. Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers. Hum Psychopharm 2003;18:291-299.
88. Silverstone T. Dopamine in manic depressive illness. A pharmacological synthesis. J Affect Disord 1985;8:225-231.
89. Jacobs D, Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med 1986;16:323-329.
90. Nurnberger JI Jr., Gershon ES, Simmons S, Ebert M, Kessler LR, Dibble ED et al. Behavioral, biochemical and neuroendocrine responses to amphetamine in normal twins and 'well-state' bipolar patients. Psychoneuroendocrinology 1982;7:163-176.
91. Ko GN, Leckman JF, Heninger GR. Induction of rapid mood cycling during L-dopa treatment in a bipolar patient. Am J Psychiatry 1981;138:1624-1625.
92. Harsch HH, Miller M, Young LD. Induction of mania by L-dopa in a nonbipolar patient. J Clin Psychopharmacol 1985;5:338-339.
93. Murphy DL. L-dopa, behavioral activation and psychopathology. Res Publ Assoc Res Nerv Ment Dis 1972;50:472-493.
94. Fisher G, Pelonero AL, Ferguson C. Mania precipitated by prednisone and bromocriptine. Gen Hosp Psychiatry 1991;13:345-346.
95. Kemperman CJ, Zwanikken GJ. Psychiatric side effects of bromocriptine therapy for postpartum galactorrhoea. J R Soc Med 1987;80:387-388.
96. Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulantassociated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull 2008;41:37-47.
97. McTavish SF, McPherson MH, Harmer CJ, Clark L, Sharp T, Goodwin GM et al. Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry 2001;179:356-360.
98. Scarna A, Gijsman HJ, McTavish SF, Harmer CJ, Cowen PJ, Goodwin GM. Effects of a branched-chain amino acid drink in mania. Br J Psychiatry 2003;182:210-213.
99. Anand A, Darnell A, Miller HL, Berman RM, Cappiello A, Oren DA et al. Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. Biol Psychiatry 1999;45:972-978.
100. van Enkhuizen J, Geyer MA, Halberstadt AL, Zhuang X, Young JW. Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. J Affect Disord 2014;155:247-254.
101. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522.
102. Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 2006;29:259-264.
103. Martinez-Martin P, Damian J. Parkinson disease: depression and anxiety in Parkinson disease. Nat Rev Neurol 2010;6:243-245.
104. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-1322.
105. Parker G, Brotchie H. Mood effects of the amino acids tryptophan and tyrosine: 'Food for Thought' III. Acta Psychiatr Scand 2011;124:417-426.
106. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007;12:331-359.
107. Greil W, Haberle A, Haueis P, Grohmann R, Russmann S. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord 2012;136:534-542.
108. Hayes J, Prah P, Nazareth I, King M, Walters K, Petersen I et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PloS One 2011;6: e28725.
109. Hooshmand F, Miller S, Dore J, Wang PW, Hill SJ, Portillo N et al. Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011. J Affect Disord 2014;155:283-287.
110. Walpoth-Niederwanger M, Kemmler G, Grunze H, Weiss U, Hortnagl C, Strauss R et al. Treatment patterns in inpatients with bipolar disorder at a psychiatric university hospital over a 9-year period: focus on mood stabilizers. Int Clin Psychopharmacol 2012;27:256-266.
111. Ketter TA, Miller S, Dell'Osso B, Calabrese JR, Frye MA, Citrome L. Balancing benefits and harms of treatments for acute bipolar depression. J Affect Disord 2014;169: S24-S33.
112. Nolen WA. Dopamine and mania. The effects of trans- and cis-clopenthixol in a double-blind pilot study. J Affect Disord 1983;5:91-96.
113. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016;30:495-553.
114. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004;101:5099-5104.
115. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potentialmechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 2013;27:135-153.
116. Gambarana C, Ghiglieri O, Masi F, Scheggi S, Tagliamonte A, De Montis MG. The effects of long-term administration of rubidium or lithium on reactivity to stress and on dopamine output in the nucleus accumbens in rats. Brain Res 1999;826:200-209.
117. Ichikawa J, Dai J, Meltzer HY. Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT(1 A) receptor agonism. Brain Res 2005;1049:182-190.
118. Ferrie LJ, Gartside SE, Martin KM, Young AH, McQuade R. Effect of chronic lithium treatment on D2/3 autoreceptor regulation of dopaminergic function in the rat. Pharmacol Biochem Behav 2008;90:218-225.
119. Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK. Placebocontrolled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry 2012;73:103-112.
120. Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004;20:131-138.
121. Dell'osso B, Timtim S, Hooshmand F, Miller S, Wang PW, Hill SJ et al. Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder. J Affect Disord 2013;150:130-135.
122. El-Mallakh RS, Penagaluri P, Kantamneni A, Gao Y, Roberts RJ. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q 2010;81:207-213.
123. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatmentresistant bipolar depression. Am J Psychiatry 2004;161:564-566.
124. Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002;4:307-314.
125. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001;34:137-141.
126. Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000;12:137-140.
127. Zarate CA Jr., Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60.
128. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord 2004;6:416-420.
129. El-Mallakh RS. An open study of methylphenidate in bipolar depression. Bipolar Disord 2000;2:56-59.
130. Lydon E, El-Mallakh RS. Naturalistic long-term use of methylphenidate in bipolar disorder. J Clin Psychopharmacol 2006;26:516-518.
131. Parker G, Brotchie H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr Scand 2010;121:308-314.
132. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and metaanalysis of randomized controlled trials. J Clin Psychiatry 2013;74:1101-1107.
133. Dell'Osso B, Ketter TA, Cremaschi L, Spagnolin G, Altamura AC. Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression. Curr Psychiatry Rep 2013;15:378.
134. Rao JS, Kellom M, Reese EA, Rapoport SI, Kim HW. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J Affect Disord 2012;136:63-71.
135. Lee FJ, Pei L, Liu F. Disruption of the dopamine transporter-dopamine D2 receptor interaction in schizophrenia. Synapse (New York, NY) 2009;63:710-712.
136. Amsterdam JD, Newberg AB. A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls. Neuropsychobiology 2007;55:167-170.
137. Nasr S. Modafinil as adjunctive therapy in depressed outpatients. Ann Clin Psychiatry 2004;16:133-138.
138. Nasr S, Wendt B, Steiner K. Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. J Affect Disord 2006;95:111-114.
139. Heijnen WT, De Fruyt J, Wierdsma AI, Sienaert P, Birkenhager TK. Efficacy of tranylcypromine in bipolar depression: a systematic review. J Clin Psychopharmacol 2015;35:700-705.
140. Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 2013;27:789-797.
141. Selle V, Schalkwijk S, Vazquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014;47:43-52.
142. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005;7:268-274.
143. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18:1715-1726.
144. Chung S, Lee EJ, Yun S, Choe HK, Park SB, Son HJ et al. Impact of circadian nuclear receptor REV-ERBalpha on midbrain dopamine production and mood regulation. Cell 2014;157:858-868.
145. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 2011;16:67-75.
146. Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, Marangell LB et al. Manic symptoms during depressive episodes in 1, 380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2009;166:173-181.
147. Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis. J Clin Psychiatry 2015;76:728-734.
148. Hazy TE, Frank MJ, O'Reilly RC. Neural mechanisms of acquired phasic dopamine responses in learning. Neurosci Biobehav Rev 2010;34:701-720.
149. Hall H, Wedel I, Halldin C, Kopp J, Farde L. Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes. J Neurochem 1990;55:2048-2057.
150. Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 2015;72:316-324.